Hughes Maria L R, Liu Bonan, Halls Michelle L, Wagstaff Kylie M, Patil Rahul, Velkov Tony, Jans David A, Bunnett Nigel W, Scanlon Martin J, Porter Christopher J H
From Drug Delivery, Disposition and Dynamics.
Drug Discovery Biology.
J Biol Chem. 2015 May 29;290(22):13895-906. doi: 10.1074/jbc.M114.605998. Epub 2015 Apr 6.
Nuclear hormone receptors (NHRs) regulate the expression of proteins that control aspects of reproduction, development and metabolism, and are major therapeutic targets. However, NHRs are ubiquitous and participate in multiple physiological processes. Drugs that act at NHRs are therefore commonly restricted by toxicity, often at nontarget organs. For endogenous NHR ligands, intracellular lipid-binding proteins, including the fatty acid-binding proteins (FABPs), can chaperone ligands to the nucleus and promote NHR activation. Drugs also bind FABPs, raising the possibility that FABPs similarly regulate drug activity at the NHRs. Here, we investigate the ability of FABP1 and FABP2 (intracellular lipid-binding proteins that are highly expressed in tissues involved in lipid metabolism, including the liver and intestine) to influence drug-mediated activation of the lipid regulator peroxisome proliferator-activated receptor (PPAR) α. We show by quantitative fluorescence imaging and gene reporter assays that drug binding to FABP1 and FABP2 promotes nuclear localization and PPARα activation in a drug- and FABP-dependent manner. We further show that nuclear accumulation of FABP1 and FABP2 is dependent on the presence of PPARα. Nuclear accumulation of FABP on drug binding is driven largely by reduced nuclear egress rather than an increased rate of nuclear entry. Importin binding assays indicate that nuclear access occurs via an importin-independent mechanism. Together, the data suggest that specific drug-FABP complexes can interact with PPARα to effect nuclear accumulation of FABP and NHR activation. Because FABPs are expressed in a regionally selective manner, this may provide a means to tailor the patterns of NHR drug activation in a tissue-specific manner.
核激素受体(NHRs)调节着控制生殖、发育和新陈代谢等方面的蛋白质表达,是主要的治疗靶点。然而,NHRs广泛存在并参与多种生理过程。因此,作用于NHRs的药物通常受到毒性限制,且往往是在非靶器官产生毒性。对于内源性NHR配体,细胞内脂质结合蛋白,包括脂肪酸结合蛋白(FABPs),可以将配体转运至细胞核并促进NHR激活。药物也会与FABPs结合,这增加了FABPs同样调节药物在NHRs上活性的可能性。在此,我们研究了FABP1和FABP2(在包括肝脏和肠道在内的参与脂质代谢的组织中高表达的细胞内脂质结合蛋白)影响药物介导的脂质调节因子过氧化物酶体增殖物激活受体(PPAR)α激活的能力。我们通过定量荧光成像和基因报告分析表明,药物与FABP1和FABP2的结合以药物和FABP依赖的方式促进核定位和PPARα激活。我们进一步表明,FABP1和FABP2的核积累依赖于PPARα的存在。药物结合时FABP的核积累主要是由核输出减少而非核输入速率增加驱动的。输入蛋白结合分析表明,核进入是通过一种不依赖于输入蛋白的机制发生的。总之,数据表明特定的药物 - FABP复合物可以与PPARα相互作用,从而影响FABP的核积累和NHR激活。由于FABPs以区域选择性方式表达,这可能提供一种以组织特异性方式调整NHR药物激活模式的方法。